Bristol-Myers Squibb Company announced changes to its U.S. geographic footprint that will strengthen capabilities of the company's R&D hubs in central New Jersey, the San Francisco Bay Area and Cambridge, Massachusetts, while further integrating biologics development with clinical manufacturing at key sites to foster greater speed and collaboration.
The changes follow previously announced investments to modernize workspace with the development of a state-of-the-art research facility in Cambridge, the expansion of its Redwood City research campus in the San Francisco Bay Area, and recently opened Princeton Pike facility in Lawrenceville, New Jersey.
Bristol-Myers Squibb will make investments in the construction of a new R&D building at the company’s Lawrenceville, New Jersey, campus that will co-locate lab-based Discovery and Translational Medicine activities; construction at its New Brunswick, New Jersey, facility to support biologics development; and continue expansion of its biologics campus in Devens, Massachusetts.
The company also announced it intends to initiate a phased multi-year closure of its Hopewell, New Jersey, site by mid-2020 and will not renew its lease at the Lake Union Steam Plant site in Seattle, Washington, in 2019. The company confirmed previously announced plans to close its Wallingford, Connecticut, site by the end of 2018, and also announced it will no longer build a Connecticut Development site. The company expects many of the roles from Wallingford, Hopewell and Seattle will transition to other U.S. locations.